DipathAI Showcases DeepPathAI Foundation Model and End-to-End Digital Pathology Solutions at WAIC 2026 Amid IPO Filing

Jul 22, 2026 19:56 CST Updated 19:56

Dipath

AI-Assisted Diagnostic Tool Developer

Midsummer on the Huangpu River, Intelligence Ignites the Future. From July 17 to 20, the 2026 World Artificial Intelligence Conference (WAIC 2026) grandly opened in Shanghai. As a highly influential premier international event in the global artificial intelligence field, the conference gathered industry experts, academicians, scholars, and leading sci-tech innovation enterprises from around the world. It showcased cutting-edge global AI innovations, serving as a vital platform for gaining insights into industry development trends and connecting with global innovation resources.Leveraging MetaX’s full-stack domestic computing power infrastructure, Dipath showcased its self-developed DeepPathAI foundational pathology large model and its end-to-end digital-intelligent pathology solution at the MetaX booth (H2-B401). This joint exhibition demonstrated to the global industry the core strength of its original AI+pathology technologies and its vision for global expansion.

Computing Power Foundation, Self-Developed Native

For two decades of deep cultivation in the field of AI pathology, Dipath has consistently adhered to independent research and development of its underlying technologies.Through deep adaptation to the MetaX domestic computing power platform, DeepPathAI further explores synergistic pathways spanning underlying computing infrastructure, model capabilities, and scenario-based applications, thereby facilitating the implementation of domestically developed digital intelligence pathology solutions.Technical Foundation.Centered on the digitalization and intelligent development of pathology departments, the company has built an integrated software-hardware product matrix covering the entire pathology diagnosis workflow. The product line includes hardware and software terminals such as the D-PathScan-AI series large-model scanners, D-CleverEyePro intelligent microscopes, D-PathAI intelligent pathology-assisted diagnostic system, and D-PathPIS pathology information management system.

The complete solution covers digital pathology slides.key components such as digitization, image management, AI-assisted diagnosis, information management, and remote diagnosis can be flexibly configured based on the operational foundation and construction needs of different medical institutions, helping pathology departments gradually build more efficient, standardized, and scalable digital-intelligent workflows.

Previously, this mature solution was presented at multiple domestic pathology academic annual conferences and received widespread recognition from industry experts. Leveraging WAIC, a world-class AI platform, it now showcases China’s original technological breakthroughs in the digitalization and intelligence of pathology to the global medical and artificial intelligence industries.

The booth attracted a steady stream of visitors. The Dipath team introduced the collaborative workflow between large language models and hardware-software systems, engaging in in-depth discussions with attendees on hospital infrastructure development, model validation, and future industrial collaboration opportunities. NumerousAI R&D professionals from both domestic and international markets, clinical pathologists, and industry investors flocked to engage in discussions and experience the system firsthand, gaining an intuitive understanding of the various intelligent assisted diagnostic features of the DeepPath AI large language model.The human-AI collaborative diagnostic concept of “You Think, AI Sees” fully demonstrates the innovative strength of domestically produced medical AI and has garnered widespread attention.

Based in China, Going Global

As a global AI exchange platform, WAIC also serves as an important window for Dipath to broaden its international horizons and showcase cutting-edge technological achievements. Currently, the company’s national academic tour is progressing in an orderly manner, with multiple regional pathology academic conferences being held successively. Looking ahead, Dipath will continue to iterate its DeepPathAI large pathology model and constantly optimize its full range of software and hardware products. Domestically, it will steadily promote the implementation of digital-intelligent pathology technologies across medical institutions at all levels; internationally, leveraging global industry exhibitions, it will share secure, autonomous, and controllable Chinese-made AI pathology solutions with peers both in China and overseas.

Looking ahead, Dipath will continue to deepen its core proprietary technologies in large pathology models, solidify the foundation of independent innovation, and collaborate with industry, academia, research institutions, and medical practitioners to foster domestic and international exchanges. The company strives to promote broader global recognition of Chinese-made digital intelligence pathology technologies, leveraging artificial intelligence to continuously enhance global pathological diagnosis and treatment capabilities.

ABOUT US

Dipath | About Us

Dipath, founded in 2017, has been deeply engaged in the field of AI + digital pathology for two decades. Adhering to the mission of "Intelligence Illuminates Pathology, Making Precision Medicine Accessible," it is a leading benchmark enterprise in China's intelligent digital pathology and AI diagnostics sector. The company has received over 200 honors, including recognition as a National High-Tech Enterprise, a Zhejiang Province Specialized, Refined, Differential, and Innovative (SRDI) Small and Medium-sized Enterprise, a Hangzhou Quasi-Unicorn, and a Zhejiang Science and Technology New Little Dragon. Since being classified as an enterprise above designated size in 2023, its annual revenue growth rate has consistently remained above 70%, demonstrating strong development momentum.

On January 6, 2026, Professor Yang Lin, founder of the company and head of the Artificial Intelligence and Biomedical Imaging Laboratory at Westlake University, donated equity to Westlake University on behalf of the enterprise. This donation aims to deepen industry-academia-research-medical collaboration and promote high-quality development in cross-disciplinary innovation between medicine and engineering, as well as in the digital intelligence pathology industry.

Core Advantages

Top-tier R&D Strength

The R&D team has been deeply engaged in the field of pathological AI for over 20 years, with R&D centers established in Hangzhou, Shaanxi, and Guangdong. The company hosts a High-Tech Enterprise R&D Center and a Postdoctoral Workstation, with R&D personnel accounting for 60% of its workforce. It has led more than 40 national-level scientific research fund projects, published over 500 high-impact SCI papers, and accumulated more than 10,000 total citations.

Full-Stack Independent Innovation

Leveraging a deep integration model of industry, academia, research, and medicine centered around Westlake University, the company has built a full-chain innovation system spanning from basic scientific research to clinical translation. Driven by its fully self-developed large models, it has constructed AI-powered pathology applications covering all scenarios in cellular, tissue, and molecular pathology. The company holds more than 220 intellectual property rights, including over 80 invention patents, and has obtained 25 Class II medical device registration certificates. It was selected as a winning unit in the AI medical device innovation challenge launched by China’s Ministry of Industry and Information Technology and the National Medical Products Administration, tackling key technological bottlenecks in the industry.

Full-Scenario Product Matrix

Centered on the DeepPathAI “Shendi Mofang” foundational large model, we have developed a product portfolio comprising ZhiJie, intelligent pathology, AI-powered cervical cytology, and large-model-enabled scanners. By integrating cloud-based services such as intelligent remote consultation, pathology information management and quality control systems, intelligent standardized training platforms, and digital pathology cloud storage, we provide a comprehensive solution for building fully digital and intelligent pathology departments, covering all disease types and the entire workflow.

Large-Scale Clinical Implementation

Serving over 1,500 medical institutions, research organizations, and pharmaceutical companies globally; collaborating with nearly 100 top-tier (Grade A tertiary) hospitals in China to co-establish fully digital and intelligent pathology departments, jointly launching multiple specialty-specific large pathology models, and comprehensively enhancing the integrated capabilities in pathological diagnosis, education, and research. Conducted over 20,000 “ZhiJie” live-streamed teaching sessions and more than 30,000 real-time microscopic consultations and remote会诊, extending remote coverage to over a thousand hospitals nationwide and providing support to 1,000 grassroots healthcare institutions.

Talent Recruitment

Dipath · Global Talent Recruitment

We sincerely invite elite professionals in image algorithm engineering, software development, clinical technology, and AI agent product management to join Dipath. Together with our top-tier team, let us build a new ecosystem for pathology AI and embark on a new future of digital-intelligent healthcare.

HR Email: hr@dipath.cn

Westlake University Yang Lin Lab · Ph.D. Recruitment

Professor Yang Lin’s team is continuously recruiting Ph.D. students, focusing on cutting-edge research in artificial intelligence, biomedical imaging, digital pathology, and large medical models. We sincerely invite outstanding students to engage in interdisciplinary innovation at the intersection of medicine and engineering, jointly pursuing world-class scientific achievements.

Submission Email:yanglinlab@westlake.edu.cn